| Company Name: | Pfizer Inc | | Ticker Symbol: | PFE | | | WWW Address: | www.pfizer.com |
| CEO: | Ian C. Read | | No. of Employees: | 91,500 |
| Common Issue Type: | CS | | Business Description: | Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segmentsPrimary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 28.7 |  -0.26 | - | - | 28.97 | 29.37 | 28.83 | 32052602 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 203,575.5 | 7,093.2 | 0.73 | 1.94 | 0.88 | 13.9 | 3.3 | 31.15 - 21.40 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 28.96 | $ | | PE Ratio - LTM | 13.9 | |
| Market Capitalisation | 203,575.5 | mil |
| Latest Shares Outstanding | 7,093.2 | mil |
| Earnings pS (EPS) | 1.94 | $ |
| Dividend pS (DPS) | 0.88 | ¢ |
| Dividend Yield | 3.3 | % |
| Dividend Payout Ratio | 45 | % |
| Revenue per Employee | 644,656 | $ |
| Effective Tax Rate | 21.2 | % |
| Float | 7,183.9 | mil |
| Float as % of Shares Outstanding | 100.0 | % |
| Foreign Sales | 94,886 | mil |
| Domestic Sales | 23,086 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28.20 | % |
| Research & Devlopment (R&D) as % of Revenue | 13.20 | % |
| Gross Profit Margin | 84.2 | % |
| EBITDA Margin | 42.8 | % |
| Pre-Tax Profit Margin | 23.6 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | 8.3 | % |
| Return on Equity (ROE) | 18.9 | % |
| Return on Capital Invested (ROCI) | 13.7 | % |
| Current Ratio | 2.4 | |
| Leverage Ratio (Assets/Equity) | 2.3 | |
| Interest Cover | 10.4 | |
| Total Debt/Equity (Gearing Ratio) | 0.49 | |
| LT Debt/Total Capital | 28.0 | % |
| Working Capital pS | 5.25 | $ |
| Cash pS | 0.30 | $ |
| Book-Value pS | 11.59 | $ |
| Tangible Book-Value pS | -0.80 | $ |
| Cash Flow pS | 3.20 | $ |
| Free Cash Flow pS | 2.85 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.50 | |
| Price/Tangible Book Ratio | -36.36 | |
| Price/Cash Flow | 9.1 | |
| Price/Free Cash Flow | 10.2 | |
| P/E as % of Industry Group | 53.0 | % |
| P/E as % of Sector Segment | 75.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 04/24/2013 |
| Dividend Ex-Date | 05/07/2013 |
| Dividend Record Date | 05/09/2013 |
| Dividend Pay Date | 06/03/2013 |
| Dividend Amount | 240 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.96 |
| Current Dividend Yield | 3.3 |
| 5-Y Average Dividend Yield | 4.4 |
| Payout Ratio | 45.0 |
| 5-Y Average Payout Ratio | 70.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.8 | 99 | 316,547 | 1,608,261 |
| 4 Weeks | 31.15 | 28.42 | 31.06 | -6.8 | 87 | 357,796 | 7,155,922 |
| 13 Weeks | 31.15 | 26.82 | 27.29 | 6.1 | 97 | 322,092 | 20,291,769 |
| 26 Weeks | 31.15 | 23.87 | 23.86 | 21.4 | 99 | 323,601 | 40,126,481 |
| 52 Weeks | 31.15 | 21.40 | 22.57 | 28.3 | 100 | 313,570 | 78,079,048 |
| YTD | 31.15 | 25.33 | - | 15.5 | 99 | 329,916 | 31,341,980 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 29.31 | 29.03 | 29.27 | 27.10 | 26.33 | 0.73 | 0.81 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 6.03 | 50.3 | -0.24 |
| Income | 9.84 | 53.4 | 22.65 |
| Dividend | -7.03 | 38.1 | 9.41 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 0.67 | NA | -2.12 |
| Normalized Inc. | 2.36 | NA | 6.12 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -12.4 | -12.4 | -12.5 |
| Earnings % | 53.4 | 53.4 | 45.2 |
| EPS % | 58.3 | 58.3 | 51.6 |
| EPS $ | 0.14 | 0.14 | 0.66 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 17.65 |
| Current Ratio | 2.1 |
| Quick Ratio (Acid Test) | 1.9 |
| Liquidity Ratio (Cash) | 1.14 |
| Receivables Turnover | 2.6 |
| Average Collection Period | 138 |
| Working Capital/Equity | 40.4 |
| Working Capital pS | 4.51 |
| Cash-Flow pS | 3.05 |
| Free Cash-Flow pS | 2.75 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.05 |
| Financial Leverage Ratio (Assets/Equity) | 2.3 |
| Debt Ratio | 56.3 |
| Total Debt/Equity (Gearing Ratio) | 0.46 |
| LT Debt/Equity | 0.38 |
| LT Debt/Capital Invested | 67.6 |
| LT Debt/Total Liabilities | 29.7 |
| Interest Cover | 8.9 |
| Interest/Capital Invested | 0.97 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 104.51 |
| Tobin's Q Ratio | 1.11 |
| Current P/E Ratio - LTM | 13.90 |
| Enterprise Value (EV)/EBITDA | 10.83 |
| Enterprise Value (EV)/Free Cash Flow | 11.59 |
| Dividend Yield | 3.3 |
| Price/Tangible Book Ratio - LTM | -36.36 |
| Price/Book Ratio - LTM | 2.50 |
| Price/Cash Flow Ratio | 9.1 |
| Price/Free Cash Flow Ratio - LTM | 10.2 |
| Price/Sales Ratio | 3.57 |
| P/E Ratio (1 month ago) - LTM | 14.8 |
| P/E Ratio (26 weeks ago) - LTM | 18.5 |
| P/E Ratio (52 weeks ago) - LTM | 18.1 |
| 5-Y High P/E Ratio | 20.2 |
| 5-Y Low P/E Ratio | 9.4 |
| 5-Y Average P/E Ratio | 15.3 |
| Current P/E Ratio as % of 5-Y Average P/E | 91 |
| P/E as % of Industry Group | 53.0 |
| P/E as % of Sector Segment | 75.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 14.6 |
| PER SHARE FIGURES |
| LT Debt pS | 4.27 |
| Current Liabilities pS | 3.93 |
| Tangible Book Value pS - LTM | -0.80 |
| Book Value pS - LTM | 11.59 |
| Capital Invested pS | 15.83 |
| Cash pS - LTM | 0.30 |
| Cash Flow pS - LTM | 3.20 |
| Free Cash Flow pS - LTM | 2.85 |
| Earnings pS (EPS) | 1.94 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 33.89 |
| Free Cash Flow Margin 5YEAR AVG | 0.74 |
| Net Profit Margin | 24.7 |
| Net Profit Margin - 5YEAR AVRG. | 17.0 |
| Equity Productivity | 0.73 |
| Return on Equity (ROE) | 18.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 12.5 |
| Capital Invested Productivity | 0.53 |
| Return on Capital Invested (ROCI) | 13.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 9.0 |
| Assets Productivity | 0.30 |
| Return on Assets (ROA) | 7.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | 5.6 |
| Gross Profit Margin | 84.2 |
| Gross Profit Margin - 5YEAR AVRG. | 84.1 |
| EBITDA Margin - LTM | 42.8 |
| EBIT Margin - LTM | 26.0 |
| Pre-Tax Profit Margin | 20.5 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 18.7 |
| Effective Tax Rate | 21.2 |
| Effective Tax Rate - 5YEAR AVRG. | 20.4 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 432 |
| Revenue per Employee | 644,656 |
| Net Income per Employee | 159,541 |
| Average Collection Period | 132 |
| Receivables Turnover | 2.6 |
| Day's Inventory Turnover Ratio | 300 |
| Inventory Turnover | 1.2 |
| Inventory/Sales | 12.0 |
| Accounts Payble/Sales | 7.23 |
| Assets/Revenue | 3.33 |
| Net Working Capital Turnover | 1.80 |
| Fixed Assets Turnover | 0.47 |
| Total Assets Turnover | 0.3 |
| Revenue per $ Cash | 5.68 |
| Revenue per $ Plant | 4.08 |
| Revenue per $ Common Equity | 0.73 |
| Revenue per $ Capital Invested | 0.53 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 28.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 29.1 |
| Research & Devlopment (R&D) as % of Revenue | 13.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 13.3 |
|
|  
| | |  |  | |
| |
